Full Archive
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
Journal for Immunotherapy for Cancer 2023 October [Link] Krisztian Homicsko, Panagiota Zygoura, Maxim Norkin, Stephanie Tissot, Nicholas Shakarishvili, Sanjay Popat, Alessandra Curioni-Fontecedro, Mary O’Brien, Anthony Pope, Riyaz Shah, Patricia Fisher, James Spicer, Amy Roy, David Gilligan, Sylvie Rusakiewicz, Ekaterina Fortis, Nesa Marti, Roswitha Kammler, Stephen P Finn, Georges Coukos, Urania Dafni, Solange Peters, Rolf A…
Read MorePreventive and therapeutic opportunities: targeting BAP1 and/or HMGB1 pathways to diminish the burden of mesothelioma
Journal of Translational Medicine 2023 October 25 [Link] Michele Carbone, Michael Minaai, Yasutaka Takinishi, Ian Pagano, Haining Yang Abstract Mesothelioma is a cancer typically caused by asbestos. Mechanistically, asbestos carcinogenesis has been linked to the asbestos-induced release of HMGB1 from the nucleus to the cytoplasm, where HMGB1 promotes autophagy and cell survival, and to the…
Read MoreQuality of life in patients with PICC diagnosed with mesothelioma: Results of a multicenter epidemiological survey (LifePICC)
The Journal of Vascular Access 2023 October 24 [Link] Tatiana Bolgeo, Roberta Di Matteo, Stefania Crivellari, Denise Gatti, Antonella Cassinari, Carmela Riccio, Antonina De Angelis, Sara Delfanti, Elisabetta Ferrero, Claudia Gnani, Giuseppe Riili, Antonio Maconi Abstract Background: Pleural mesothelioma (PM) is a rare and aggressive cancer. PICC devices are widely used in cancer patients. The…
Read MorePerioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
Interdisciplinary Cardiovascular Thoracic Surgery 2023 November 2 [Link] Luigi Ventura, Michelle Lee, Ralitsa Baranowski, Joanne Hargrave, Michael Sheaff, David Waller Abstract Objectives: The goal was to evaluate the accuracy of preoperative histological assessment and the factors affecting the accuracy and the subsequent effect on postoperative survival after surgical treatment for malignant pleural mesothelioma (MPM). Methods:…
Read MoreFunctional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor
Cancer Immunology, Immunotherapy 2023 October 18 [Link] Derrick McCarthy, Michael Lofgren, Amy Watt, Holly Horton, Philippe Kieffer-Kwon, Jian Ding, Sebastian Kobold, Patrick A Baeuerle, Robert Hofmeister, Dario A Gutierrez, Robert Tighe Abstract T cells expressing a mesothelin (MSLN)-specific T cell receptor fusion construct (TRuC®), called TC-210, have demonstrated robust antitumor activity in preclinical models of…
Read MoreClaudin-4 immunocytochemistry is specific and sensitive for the diagnosis of malignant carcinomatous effusions: Results from a pilot study
Diagnostic Cytopathology 2023 October 13 [Link] Vanlal Hruaii, Balamurugan Thirunavukkarasu, Vindhya Prabha, Sandeep Mathur, Venkateswaran K Iyer, Aruna Nambirajan, Deepali Jain Abstract Background: Claudin-4, a tight junction associated protein expressed in epithelial cells, is purported as a highly specific and sensitive marker for epithelial malignancies. Our aim was to assess the sensitivity, specificity and real-time…
Read MoreComprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma
Medicine 2023 October 13 [Link] Jiren Weng, Jing Chen Abstract To explore the influence and effect of tumor microenvironment on the development of malignant mesothelioma using machine learning methods. 87 open cases were downloaded from the Cancer Genome Atlas database including transcriptome data, clinical data, and mutation data. The immune, stromal, and estimate scores were…
Read MoreEffects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells
Molecular Cancer Therapeutics 2023 October 7 [Link] Soichi Hirai, Tadaaki Yamada, Yuki Katayama, Masaki Ishida, Hayato Kawachi, Yohei Matsui, Ryota Nakamura, Kenji Morimoto, Mano Horinaka, Toshiyuki Sakai, Yoshitaka Sekido, Shinsaku Tokuda, Koichi Takayama Abstract Few treatment options exist for pleural mesothelioma (PM), which is a progressive malignant tumor. However, the efficacy of molecular-targeted monotherapy is…
Read MoreGelatinous Pleural Effusion: A Diagnostic Challenge for Pleural Mesothelioma in an 80-Year-Old Man
American Journal of Case Reports 2023 October 4 [Link] Ali M Ibnian, Obaid Ullah Khan, Richard Chan, Umesh Bangalore Lakshminarayana, Fasiha Kiran, Sarah Abed, Rahim Abbas, Ahsan Amir, Noran K Al-Kofahi Abstract BACKGROUND Gelatinous pleural effusion, due to raised hyaluronic acid, can be associated with pleural infection and malignancies, such as tuberculosis, metastatic pleural disease,…
Read MoreUroplakin-IIIb as a novel immunohistochemical marker for mesothelioma
Human Pathology 2023 September 28 [Link] Derek M van Pel, Simon Cheung, Diana N Ionescu, Andrew Churg Abstract Distinguishing mesothelioma from non-small cell lung carcinoma often requires a battery of immunohistochemical stains, as many traditional markers used in mesothelioma lack sufficient specificity to allow them to be used alone. A recent large-scale TMA screen identified…
Read More